Efficacy And Safety Of Febuxostat In Renal Transplant Recipients With Hyperuricemia

L. Liu¹, J. Jiang¹, Q. Fu², S. Long³, H. Zhang², X. Su², J. Li², C. Wu², R. Deng², W. Zhang³, C. Wang²

¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Organ transplant center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ³Information Data Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Meeting: 2019 American Transplant Congress

Abstract number: C205

Keywords: Kidney transplantation, Metabolic complications, Pharmacokinetics, Prognosis

Session Information

Session Name: Poster Session C: Kidney: Cardiovascular and Metabolic

Session Type: Poster Session

Date: Monday, June 3, 2019

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: To assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients.

*Methods: A total number of 124 renal transplant patients with hyperuricemia who were prescribed febuxostat between June 2016 and July 2018 were retrospectively analyzed. The initial dose of febuxostat was 10-40 mg/d depending on serum uric acid level and body weight. The uric acid (UA), liver function and renal function parameters before and 3 months after febuxostat treatment was compared. Adverse events and patient and renal allograft survival were recorded throughout the follow-up period.

*Results: Serum uric acid was significantly decreased after three months of febuxostat treatment from 501.21 ± 71.7 μmol/L to 374.7 ± 94.5 μmol/L (Table 1, p<0.001). 82 out of 124 patients (66.1%) reached to normal UA level at month 3 after febuxostat treatment. Estimated glomerular filtration rate (eGFR) was maintained (54.4 ± 15.4 vs 55.8 ± 16.2 mL/min/1.73m², p =0.074). No severe adverse event was observed. All patients and renal grafts survived during the follow-up period.

Table 1. Parameters changes before and after febuxostat treatment
	Before treatment	3 months after treatment	P-value
Serum uric acid(μmol/L)	501.21 ± 71.7	374.7 ± 94.5	<0.001
Serum creatinine(μmol/L)	127.7 ± 36.9	126.7 ± 39.8	0.063
eGFR(ml/min/1.73m²)	54.4 ± 15.4	55.8 ± 16.2	0.074
WBC(10⁹/L)	8.0 ± 2.6	7.3 ± 2.3	<0.05
Hb(g/L)	121.6 ± 19.8	131.6 ± 17.6	<0.001

*Conclusions: Febuxostat is effective and safe in the treatment of hyperuricemia in renal transplant recipients.

To cite this abstract in AMA style:

Liu L, Jiang J, Fu Q, Long S, Zhang H, Su X, Li J, Wu C, Deng R, Zhang W, Wang C. Efficacy And Safety Of Febuxostat In Renal Transplant Recipients With Hyperuricemia [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/efficacy-and-safety-of-febuxostat-in-renal-transplant-recipients-with-hyperuricemia/. Accessed November 21, 2024.

« Back to 2019 American Transplant Congress